{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:17:33Z","timestamp":1790695053525,"version":"4.1.0"},"reference-count":38,"publisher":"American Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"vor","delay-in-days":39,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100008871","name":"JDRF","doi-asserted-by":"publisher","award":["5-CDA-2015-89-A-B"],"award-info":[{"award-number":["5-CDA-2015-89-A-B"]}],"id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008871","name":"JDRF","doi-asserted-by":"publisher","award":["17-2013-311"],"award-info":[{"award-number":["17-2013-311"]}],"id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK-072381"],"award-info":[{"award-number":["DK-072381"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK-082841"],"award-info":[{"award-number":["DK-082841"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK-41526"],"award-info":[{"award-number":["DK-41526"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Patients with type 1 diabetes (T1D) with impaired renal function are at increased risk for end-stage renal disease (ESRD). Although the rate of progression varies, determinants and mechanisms of this variation are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>We examined serum metabolomic profiles associated with variation in renal function decline in participants with T1D (the Joslin Kidney Study prospective cohort). One hundred fifty-eight patients with proteinuria and chronic kidney disease stage 3 were followed for a median of 11 years to determine estimated glomerular filtration rate slopes from serial measurements of serum creatinine and to ascertain time to onset of ESRD. Baseline serum samples were subjected to global metabolomic profiling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>One hundred ten amino acids and purine and pyrimidine metabolites were detected in at least 80% of participants. Serum levels of seven modified metabolites (C-glycosyltryptophan, pseudouridine, O-sulfotyrosine, N-acetylthreonine, N-acetylserine, N6-carbamoylthreonyladenosine, and N6-acetyllysine) were associated with renal function decline and time to ESRD (P &amp;lt; 0.001) independent of the relevant clinical covariates. The significant metabolites correlated with one another and with the indices of tubular injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>This prospective cohort study in participants with T1D, proteinuria, and impaired renal function at baseline demonstrated that patients with increased circulating levels of certain modified metabolites experience faster renal function decline, leading to ESRD. Whether some of these candidate metabolites are risk factors or just prognostic biomarkers of progression to ESRD in T1D needs to be determined.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc16-0173","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T21:31:07Z","timestamp":1484343067000},"page":"383-390","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":110,"title":["Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease"],"prefix":"10.2337","volume":"40","author":[{"given":"Monika A.","family":"Niewczas","sequence":"first","affiliation":[{"name":"Research Division, Joslin Diabetes Center, Boston, MA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Mathew","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Croall","sequence":"additional","affiliation":[{"name":"Research Division, Joslin Diabetes Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeman","family":"Byun","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Major","sequence":"additional","affiliation":[{"name":"Research Division, Joslin Diabetes Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatta S.","family":"Sabisetti","sequence":"additional","affiliation":[{"name":"Renal Division, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Smiles","sequence":"additional","affiliation":[{"name":"Research Division, Joslin Diabetes Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph V.","family":"Bonventre","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"Renal Division, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramaniam","family":"Pennathur","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej S.","family":"Krolewski","sequence":"additional","affiliation":[{"name":"Research Division, Joslin Diabetes Center, Boston, MA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"key":"2022031301502237300_B1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2337\/dc15-0184","article-title":"Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes","volume":"38","author":"Krolewski","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031301502237300_B2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/ki.2012.189","article-title":"The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease","volume":"82","author":"Skupien","year":"2012","journal-title":"Kidney Int"},{"key":"2022031301502237300_B3","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/ki.2013.497","article-title":"Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study","volume":"85","author":"Niewczas","year":"2014","journal-title":"Kidney Int"},{"key":"2022031301502237300_B4","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1681\/ASN.2008121233","article-title":"Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria","volume":"20","author":"Merchant","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2022031301502237300_B5","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.2337\/db15-0116","article-title":"Circulating TGF-\u03b21-regulated miRNAs and the risk of rapid progression to ESRD in type 1 diabetes","volume":"64","author":"Pezzolesi","year":"2015","journal-title":"Diabetes"},{"key":"2022031301502237300_B6","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1681\/ASN.2012101006","article-title":"A combined epidemiologic and metabolomic approach improves CKD prediction","volume":"24","author":"Rhee","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2022031301502237300_B7","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2337\/db14-0509","article-title":"Metabolomics and diabetes: analytical and computational approaches","volume":"64","author":"Sas","year":"2015","journal-title":"Diabetes"},{"key":"2022031301502237300_B8","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1681\/ASN.2013020126","article-title":"Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease","volume":"24","author":"Sharma","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2022031301502237300_B9","article-title":"A metabolome-wide association study of kidney function and disease in the general population","author":"Sekula","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2022031301502237300_B10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1681\/ASN.2010040354","article-title":"Risk for ESRD in type 1 diabetes remains high despite renoprotection","volume":"22","author":"Rosolowsky","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2022031301502237300_B11","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1681\/ASN.V76930","article-title":"Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin\/creatinine ratio","volume":"7","author":"Warram","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"2022031301502237300_B12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031301502237300_B13","volume-title":"USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States","author":"U.S. Renal Data System","year":"2013"},{"key":"2022031301502237300_B14"},{"key":"2022031301502237300_B15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1758-2946-2-9","article-title":"Organization of GC\/MS and LC\/MS metabolomics data into chemical libraries","volume":"2","author":"Dehaven","year":"2010","journal-title":"J Cheminform"},{"key":"2022031301502237300_B16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0192623309336152","article-title":"Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats","volume":"37","author":"Ohta","year":"2009","journal-title":"Toxicol Pathol"},{"key":"2022031301502237300_B17","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/ki.2015.199","article-title":"Biomarkers of rapid chronic kidney disease progression in type 2 diabetes","volume":"88","author":"Looker","year":"2015","journal-title":"Kidney Int"},{"key":"2022031301502237300_B18","doi-asserted-by":"crossref","first-page":"F157","DOI":"10.1152\/ajprenal.00443.2011","article-title":"Elevated urinary excretion of immunoglobulins in nonproteinuric patients with type 1 diabetes","volume":"303","author":"Gohda","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031301502237300_B19","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1681\/ASN.2013070758","article-title":"Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes","volume":"25","author":"Sabbisetti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022031301502237300_B20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/ki.2010.404","article-title":"Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-\u03b2-D-glucosaminidase","volume":"79","author":"Vaidya","year":"2011","journal-title":"Kidney Int"},{"key":"2022031301502237300_B21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"key":"2022031301502237300_B22","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1681\/ASN.2011121175","article-title":"Normal and pathologic concentrations of uremic toxins","volume":"23","author":"Duranton","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022031301502237300_B23","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1681\/ASN.2009111132","article-title":"Metabolite profiling identifies markers of uremia","volume":"21","author":"Rhee","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2022031301502237300_B24","doi-asserted-by":"crossref","first-page":"e0135657","DOI":"10.1371\/journal.pone.0135657","article-title":"An enlarged profile of uremic solutes","volume":"10","author":"Tanaka","year":"2015","journal-title":"PLoS One"},{"key":"2022031301502237300_B25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/glycob\/cwi012","article-title":"Increased expression of protein C-mannosylation in the aortic vessels of diabetic Zucker rats","volume":"15","author":"Ihara","year":"2005","journal-title":"Glycobiology"},{"key":"2022031301502237300_B26","doi-asserted-by":"crossref","first-page":"13419","DOI":"10.1074\/jbc.M114.562157","article-title":"Fibulin 2, a tyrosine O-sulfated protein, is up-regulated following retinal detachment","volume":"289","author":"Kanan","year":"2014","journal-title":"J Biol Chem"},{"key":"2022031301502237300_B27","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.2337\/db12-1770","article-title":"Diabetes induces lysine acetylation of intermediary metabolism enzymes in the kidney","volume":"63","author":"Kosanam","year":"2014","journal-title":"Diabetes"},{"key":"2022031301502237300_B28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1053\/j.ajkd.2014.04.034","article-title":"Protein carbamylation in kidney disease: pathogenesis and clinical implications","volume":"64","author":"Kalim","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2022031301502237300_B29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0014-5793(84)80996-5","article-title":"Tyrosine sulfation: a post-translational modification of proteins destined for secretion","volume":"177","author":"Hille","year":"1984","journal-title":"FEBS Lett"},{"key":"2022031301502237300_B30","doi-asserted-by":"crossref","first-page":"24243","DOI":"10.1074\/jbc.R300008200","article-title":"The biology and enzymology of protein tyrosine O-sulfation","volume":"278","author":"Moore","year":"2003","journal-title":"J Biol Chem"},{"key":"2022031301502237300_B31","doi-asserted-by":"crossref","first-page":"781","DOI":"10.18388\/abp.2000_3996","article-title":"Protein C-mannosylation: facts and questions","volume":"47","author":"Furmanek","year":"2000","journal-title":"Acta Biochim Pol"},{"key":"2022031301502237300_B32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/152165400410182","article-title":"Pseudouridine in RNA: what, where, how, and why","volume":"49","author":"Charette","year":"2000","journal-title":"IUBMB Life"},{"key":"2022031301502237300_B33","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1021\/cb7001494","article-title":"Expanding the nucleotide repertoire of the ribosome with post-transcriptional modifications","volume":"2","author":"Chow","year":"2007","journal-title":"ACS Chem Biol"},{"key":"2022031301502237300_B34","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.2337\/db13-1810","article-title":"Role of transcription factor acetylation in diabetic kidney disease","volume":"63","author":"Liu","year":"2014","journal-title":"Diabetes"},{"key":"2022031301502237300_B35","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1126\/science.1179689","article-title":"Regulation of cellular metabolism by protein lysine acetylation","volume":"327","author":"Zhao","year":"2010","journal-title":"Science"},{"key":"2022031301502237300_B36","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/nm1637","article-title":"Protein carbamylation links inflammation, smoking, uremia and atherogenesis","volume":"13","author":"Wang","year":"2007","journal-title":"Nat Med"},{"key":"2022031301502237300_B37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0092-8674(00)80577-2","article-title":"Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry","volume":"96","author":"Farzan","year":"1999","journal-title":"Cell"},{"key":"2022031301502237300_B38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrneph.2014.116","article-title":"Diabetic nephropathy\u2014emerging epigenetic mechanisms","volume":"10","author":"Kato","year":"2014","journal-title":"Nat Rev Nephrol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc16-0173","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/3\/383\/548306\/dc160173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/3\/383\/548306\/dc160173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:52:47Z","timestamp":1647132767000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/40\/3\/383\/36937\/Circulating-Modified-Metabolites-and-a-Risk-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,1,13]]},"published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc16-0173","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,13]]}}}